Immunotherapy plus induction chemotherapy followed by radiotherapy alone or one cycle of concurrent chemotherapy with cisplatin vs induction chemotherapy followed by two cycles of concurrent chemotherapy with cisplatin in locoregionally advanced nasopharyngeal carcinoma - Report - MDSpire
Advertisement
Immunotherapy plus induction chemotherapy followed by radiotherapy alone or one cycle of concurrent chemotherapy with cisplatin vs induction chemotherapy followed by two cycles of concurrent chemotherapy with cisplatin in locoregionally advanced nasopharyngeal carcinoma
Comparative Analysis of Immunotherapy with Induction Chemotherapy and Radiotherapy
Overview
This study compares the efficacy and safety of immunotherapy combined with induction chemotherapy followed by radiotherapy versus induction chemotherapy followed by concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma. The findings suggest that the immunotherapy approach may improve event-free survival with lower adverse events.
Background
Locoregionally advanced nasopharyngeal carcinoma (NPC) is often treated with concurrent chemoradiotherapy, typically involving cisplatin, which can lead to significant toxicities. Recent studies indicate that incorporating immunotherapy may enhance treatment outcomes while potentially reducing the need for high-dose cisplatin. Understanding the comparative effectiveness of these treatment strategies is crucial for optimizing patient care.
Data Highlights
Outcome
Immunochemotherapy Group
IC-CCRT Group
P-value
Complete Remission
29.4% (20/68)
14.3% (15/105)
0.02
2-Year EFS
93.5%
81.1%
0.03
2-Year OS
100.0%
97.9%
0.3
Grade 3-4 Acute Adverse Events
41.1% (28 cases)
55.2% (58 cases)
N/A
Grade 3-4 Immune-Related Adverse Events
4 patients
N/A
N/A
Key Findings
Complete remission rates were significantly higher in the immunochemotherapy group compared to the IC-CCRT group (29.4% vs 14.3%, p=0.02).
The 2-year event-free survival (EFS) was better in the immunochemotherapy group (93.5% vs 81.1%, p=0.03).
Overall survival (OS) rates were similar between the two groups (100.0% vs 97.9%, p=0.3).
Grade 3-4 acute adverse events were lower in the immunochemotherapy group (41.1% vs 55.2%).
Four patients in the immunochemotherapy group developed grade 3-4 immune-related adverse events.
Clinical Implications
The findings suggest that immunotherapy combined with induction chemotherapy may offer a favorable safety profile and improved event-free survival compared to traditional concurrent chemoradiotherapy. Clinicians should consider these results when evaluating treatment options for patients with locally advanced nasopharyngeal carcinoma.
Conclusion
Immunotherapy combined with induction chemotherapy may enhance treatment outcomes for patients with locally advanced nasopharyngeal carcinoma while minimizing adverse events. Further prospective studies are needed to validate these findings.
